AR054992A1 - Pteridinas sustituidas y uso para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias - Google Patents
Pteridinas sustituidas y uso para la preparacion de un medicamento para el tratamiento de enfermedades inflamatoriasInfo
- Publication number
- AR054992A1 AR054992A1 ARP050104923A ARP050104923A AR054992A1 AR 054992 A1 AR054992 A1 AR 054992A1 AR P050104923 A ARP050104923 A AR P050104923A AR P050104923 A ARP050104923 A AR P050104923A AR 054992 A1 AR054992 A1 AR 054992A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- atoms
- heterocyclic ring
- diseases
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 3
- -1 COO-C1-alkyl 6 Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 125000001042 pteridinyl group Chemical class N1=C(N=CC2=NC=CN=C12)* 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000565 sulfonamide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004057618A DE102004057618A1 (de) | 2004-11-29 | 2004-11-29 | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054992A1 true AR054992A1 (es) | 2007-08-01 |
Family
ID=35789067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104923A AR054992A1 (es) | 2004-11-29 | 2005-11-25 | Pteridinas sustituidas y uso para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7550472B2 (enExample) |
| EP (1) | EP1828189A1 (enExample) |
| JP (1) | JP2008521775A (enExample) |
| KR (1) | KR20070090975A (enExample) |
| CN (1) | CN101065382A (enExample) |
| AR (1) | AR054992A1 (enExample) |
| AU (1) | AU2005308785A1 (enExample) |
| BR (1) | BRPI0516626A (enExample) |
| CA (1) | CA2589209A1 (enExample) |
| DE (1) | DE102004057618A1 (enExample) |
| IL (2) | IL183447A0 (enExample) |
| MX (1) | MX2007006357A (enExample) |
| NZ (1) | NZ556152A (enExample) |
| RU (1) | RU2007124328A (enExample) |
| TW (1) | TW200633711A (enExample) |
| WO (1) | WO2006056607A1 (enExample) |
| ZA (1) | ZA200703125B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004057645A1 (de) * | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| US20060198891A1 (en) | 2004-11-29 | 2006-09-07 | Francois Ravenelle | Solid formulations of liquid biologically active agents |
| DE102004057595A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057594A1 (de) * | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| WO2007135026A2 (de) * | 2006-05-24 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Substituierte pteridine als therapeutika |
| JP5352452B2 (ja) * | 2006-06-06 | 2013-11-27 | メディシノバ， インコーポレイテッド | 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法 |
| EP3102939A4 (en) * | 2014-02-05 | 2018-02-28 | Dana-Farber Cancer Institute, Inc. | AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF |
| EP4603094A2 (en) | 2017-10-23 | 2025-08-20 | Boehringer Ingelheim International GmbH | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) |
| CN113876761B (zh) * | 2020-07-01 | 2022-12-20 | 广州华真医药科技有限公司 | 磷酸二酯酶4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用 |
| WO2023104961A1 (en) | 2021-12-09 | 2023-06-15 | Boehringer Ingelheim International Gmbh | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases |
| KR20240121251A (ko) | 2021-12-09 | 2024-08-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 진행성 섬유화 간질성 폐 질환의 치료를 위한 신규한 경구 약제학적 조성물 및 투여 섭생 |
| EP4593838A1 (en) | 2022-09-28 | 2025-08-06 | Boehringer Ingelheim International GmbH | Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| DE3323932A1 (de) | 1983-07-02 | 1985-01-10 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel |
| US4560685A (en) | 1984-06-18 | 1985-12-24 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics |
| DE3445298A1 (de) | 1984-12-12 | 1986-06-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
| DE3540952C2 (de) | 1985-11-19 | 1997-08-14 | Thomae Gmbh Dr K | 2-Piperazino-pteridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| AU770551B2 (en) | 1998-12-28 | 2004-02-26 | 4-Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| DE10202468A1 (de) | 2002-01-23 | 2004-09-30 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung |
| DE102004057645A1 (de) | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057595A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057594A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen |
-
2004
- 2004-11-29 DE DE102004057618A patent/DE102004057618A1/de not_active Withdrawn
-
2005
- 2005-11-18 US US11/282,535 patent/US7550472B2/en not_active Expired - Lifetime
- 2005-11-25 JP JP2007541996A patent/JP2008521775A/ja active Pending
- 2005-11-25 AR ARP050104923A patent/AR054992A1/es unknown
- 2005-11-25 CN CNA2005800408289A patent/CN101065382A/zh active Pending
- 2005-11-25 EP EP05813409A patent/EP1828189A1/de not_active Withdrawn
- 2005-11-25 BR BRPI0516626-8A patent/BRPI0516626A/pt not_active IP Right Cessation
- 2005-11-25 AU AU2005308785A patent/AU2005308785A1/en not_active Abandoned
- 2005-11-25 MX MX2007006357A patent/MX2007006357A/es active IP Right Grant
- 2005-11-25 WO PCT/EP2005/056247 patent/WO2006056607A1/de not_active Ceased
- 2005-11-25 KR KR1020077014857A patent/KR20070090975A/ko not_active Ceased
- 2005-11-25 CA CA002589209A patent/CA2589209A1/en not_active Abandoned
- 2005-11-25 NZ NZ556152A patent/NZ556152A/en not_active IP Right Cessation
- 2005-11-25 RU RU2007124328/04A patent/RU2007124328A/ru not_active Application Discontinuation
- 2005-11-28 TW TW094141780A patent/TW200633711A/zh unknown
-
2007
- 2007-04-13 ZA ZA200703125A patent/ZA200703125B/xx unknown
- 2007-05-28 IL IL183447A patent/IL183447A0/en unknown
-
2010
- 2010-12-09 IL IL209879A patent/IL209879A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200633711A (en) | 2006-10-01 |
| ZA200703125B (en) | 2008-09-25 |
| US20060116372A1 (en) | 2006-06-01 |
| WO2006056607A1 (de) | 2006-06-01 |
| DE102004057618A1 (de) | 2006-06-01 |
| AU2005308785A1 (en) | 2006-06-01 |
| NZ556152A (en) | 2009-06-26 |
| US7550472B2 (en) | 2009-06-23 |
| IL209879A0 (en) | 2011-02-28 |
| KR20070090975A (ko) | 2007-09-06 |
| IL183447A0 (en) | 2007-09-20 |
| JP2008521775A (ja) | 2008-06-26 |
| MX2007006357A (es) | 2007-06-20 |
| CA2589209A1 (en) | 2006-06-01 |
| RU2007124328A (ru) | 2009-02-20 |
| WO2006056607A8 (de) | 2007-01-18 |
| EP1828189A1 (de) | 2007-09-05 |
| CN101065382A (zh) | 2007-10-31 |
| BRPI0516626A (pt) | 2008-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054990A1 (es) | Pteridinas sustituidas y uso de los compuestos para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias | |
| AR054991A1 (es) | Pteridinas sustituidas y su uso para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias | |
| AR054992A1 (es) | Pteridinas sustituidas y uso para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| ECSP099728A (es) | Compuestos amino-heterocíclicos | |
| UY31405A1 (es) | "piperidino-dihidrotienopirimidas sustituidas" | |
| ECSP055636A (es) | Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa | |
| AR074358A1 (es) | Derivados de pirazina como inhibidores de la fosfodiesterasa 10 | |
| AR036604A1 (es) | Derivados de 4-pirimidona 3-sustituida | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| PE20180694A1 (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il-carbamato y derivados de 1,1,1-trifluoro-4-hidroxibutan-2-il-carbamato como inhibidores de magl | |
| MX394493B (es) | Esteroides neuroactivos, composiciones, y usos de los mismos | |
| AR045113A1 (es) | Derivados sustituidos del dioxido de tiazolbenzoisotiazol, procedimiento para su preparacion y su uso | |
| AR062695A1 (es) | N-(1- ftalazin -1--il- piperidin -4-il) - amidas como moduladores del receptor ep2 | |
| AR062387A2 (es) | El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene | |
| AR038045A1 (es) | Agentes terapeuticos | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| UY26332A1 (es) | Nuevos derivados del ácido aminodicarboxílico con propiedades farmacéuticas. | |
| AR051997A1 (es) | Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos | |
| CR8831A (es) | Compuestos y metodos para el tratamiento de dislipidemia | |
| AR050297A1 (es) | Hidantoinas sustituidas | |
| AR070187A1 (es) | Derivados de dulfonamidas sustituidas | |
| AR065587A1 (es) | Aminoamidas como antagonistas de orexina | |
| AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |